IMMX (Immix Biopharma) Total Operating Expense: $41.82 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IMMX Immix Biopharma Inc IMMX
22 GF Score
Price $13.67
! 2 Warning Signs
View Full Analysis

What is Immix Biopharma Total Operating Expense?

Immix Biopharma IMMX +3.80% 22 Total Operating Expense is $41.82 Mil as of Jun. 2026. GuruFocus rates IMMX with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

Immix Biopharma's Total Operating Expense for the three months ended in Jun. 2026 was $12.46 Mil. Immix Biopharma's Total Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 was $41.82 Mil.

Immix Biopharma Total Operating Expense Related Terms

Immix Biopharma Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Immix Biopharma's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immix Biopharma Total Operating Expense Chart

Immix Biopharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial 1.35 8.22 16.14 22.68 29.96

Immix Biopharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.72 7.66 10.89 10.80 12.46
IMMX
22GF Score
Immix Biopharma Inc IMMX
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immix Biopharma Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $41.82 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $41.82 Mil mean?
Immix Biopharma (IMMX) has a Total Operating Expense of $41.82 Mil as of Jun. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Immix Biopharma and its competitors.
Is Immix Biopharma's Total Operating Expense too high?
Immix Biopharma's current Total Operating Expense is $41.82 Mil. Overall, Immix Biopharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Immix Biopharma's Total Operating Expense compare to CBIO and NVCT?
Immix Biopharma's Total Operating Expense of $41.82 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Immix Biopharma and its competitors. Immix Biopharma's current Total Operating Expense is $41.82 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immix Biopharma stock overvalued right now?
Immix Biopharma (IMMX) has a current Total Operating Expense of $41.82 Mil. The current Total Operating Expense is $41.82 Mil. Immix Biopharma's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Immix Biopharma (IMMX), the current Total Operating Expense is $41.82 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Immix Biopharma Business Description

Address 11400 West Olympic Boulevard, Suite 200, Los Angeles, CA, USA, 90064
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
22GF Score

Get the complete analysis for IMMX

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.67
Price